The Week of May 13 in Review
The week of May 13 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
FDA Approves Radium-223 for Advanced Prostate Cancer
Dr. Morris on Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC
A Guide to ASCO 2013: Key Targeted Trials
ASCO Highlights 7 Studies in Advanced Release
ASCO 2013 Abstract Roundup
Monica Fradkin on Treating With Chemotherapy and Biotherapy
Numerous Drug Classes Studied for Use in Follicular and Other Lymphomas
Dr. Debu Tripathy Describes Intratumoral Heterogeneity
Researchers Identify How Nongenetic Mechanisms of Cancer Cell Diversity Can Affect Treatment Response
Dr. Sherman Comments on Cabozantinib and Vandetanib in Medullary Thyroid Cancer
Radium RA 223 dichloride (Xofigo) has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.In advance of the 2013 ASCO annual meeting,Targeted Therapy Newsspoke with this year’s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.ASCO highlighted studies on treatment with ipilimumab and nivolumab in advanced melanoma, radiation in NSCLC, and idelalisib in chronic lymphocytic leukemia.Abstracts published in the Annual Meeting Proceedings Part I featuring late-stage data on ibrutinib, eribulin, regorafenib, sipuleucel-T, lambrolizumab, palbociclib, and more.Monica Fradkin, RN, BSN, MPH, OCN, Oncology Nursing Education Coordinator, Yale School of Nursing, Smilow Cancer Hospital at Yale-New Haven, discusses treating patients with chemotherapy and biotherapy.Follicular lymphoma is characterized by repeated treatment responses and then relapses, and researchers will need to generate a growing list of drug choices to keep pace with patients’ needs.Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.A new study suggests that even tumor cells with a common genetic background can display functional heterogeneity.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
